News
The new version will expand the classification range up to 150 beats per minute.
Mahana Therapeutics' Parallel is a three-month digital treatment that logs patients' symptoms to deliver relevant guidance and teach them condition-management skills.
This comes roughly a year after the company raised $113 million in Series B funding.
The tech company has made headlines over the past few days for its consumer health efforts related to its smartwatches.
Together, the two companies will provide healthcare teams across the continuum of care with access to real-time patient data at any stage of a patient’s healthcare journey.
The company currently has three prescription digital therapeutics available on the market.
Workpath will now integrate into Ro and offer in-home lab services.
The partnership aims to reduce mortality rates through the integration of new technologies in developing markets.
The platform will enable localised “track and trace” and workplace-wide digital COVID freedom passes for UK employers.
Also: Stanford University spinout Deepcell lands $20 million in funding and Folx raises $4.4 million.